"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
KAYEXALATE may cause some degree of gastric irritation. Anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. Also, hypokalemia, hypocalcemia, and significant sodium retention, and their related clinical manifestations, may occur (see WARNINGS). Occasionally diarrhea develops. Large doses in elderly individuals may cause fecal impaction (see PRECAUTIONS). Rare instances of colonic necrosis have been reported. Intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with KAYEXALATE, has been reported.
The following events have been reported from worldwide post marketing experience:
- Fecal impaction following rectal administration, particularly in children;
- Gastrointestinal concretions (bezoars) following oral administration;
- Gastrointestinal tract ulceration or necrosis which could lead to intestinal perforation; and,
- Rare cases of acute bronchitis and/or broncho-pneumonia associated with inhalation of particles of polystyrene sulfonate.
Read the Kayexalate (sodium polystyrene) Side Effects Center for a complete guide to possible side effects
The simultaneous oral administration of KAYEXALATE with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability.
Non-Absorbable Cation-Donating Antacids And Laxatives
Systemic alkalosis has been reported after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with KAYEXALATE. One case of grand mal seizure has been reported in a patient with chronic hypocalcemia of renal failure who was given KAYEXALATE with magnesium hydroxide as a laxative.
Intestinal obstruction due to concretions of aluminum hydroxide when used in combination with KAYEXALATE has been reported.
The toxic effects of digitalis on the heart, especially various ventricular arrhythmias and A-V nodal dissociation, are likely to be exaggerated by hypokalemia, even in the face of serum digoxin concentrations in the “normal range”. (See WARNINGS.)
Concomitant use of Sorbitol with KAYEXALATE has been implicated in cases of colonic necrosis. Therefore, concomitant administration is not recommended. (See WARNINGS.)
KAYEXALATE may decrease absorption of lithium.
KAYEXALATE may decrease absorption of thyroxine.
Read the Kayexalate Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 3/17/2016
Additional Kayexalate Information
Kayexalate - User Reviews
Kayexalate User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.